Martin Schalling

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.

Journal: Blood
Published: April 28, 2022

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.

Journal: Blood
Published: March 26, 2020

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Journal: Blood
Published: October 29, 2018

Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.

Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.

Journal: European journal of haematology
Published: March 20, 2018

The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology.

The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology.

Journal: Annals of hematology
Published: March 18, 2018

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.

Journal: Blood cancer journal
Published: August 11, 2017

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.

Journal: American journal of hematology
Published: April 26, 2017

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Journal: Leukemia
Published: March 02, 2017

Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.

Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.

Journal: British journal of haematology
Published: July 20, 2016

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Journal: Leukemia
Published: August 18, 2015

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Journal: Blood
Published: July 31, 2015

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Journal: Blood
Published: April 09, 2015
Showing 1-12 of 16

Last Updated: 09/26/2026